EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of artificial intelligence in drug screening, drug design, and clinical trials

Yuyuan Wu, Lijing Ma, Xinyi Li, Jingpeng Yang, Xinyu Rao, Yiru Hu, Jingyi Xi, Lin Tao, Jianjun Wang, Lailing Du, Gongxing Chen, Shuiping Liu

Frontiers in Pharmacology · 29.11.2024 · 15

DOI: 10.3389/fphar.2024.1459954 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.11.2024. Verfasst von Yuyuan Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of computational tools in drug discovery and development is becoming increasingly important due to the rapid development of computing power and advancements in computational chemistry and biology, improving research efficiency and reducing the costs and potential risks of preclinical and clinical trials. Machine learning, especially deep learning, a subfield of artificial intelligence (AI), has demonstrated significant advantages in drug discovery and development, including high-throughput and virtual screening, ab initio design of drug molecules, and solving difficult organic syntheses. This review summarizes AI technologies used in drug discovery and development, including their roles in drug screening, design, and solving the challenges of clinical trials. Finally, it discusses the challenges of drug discovery and development based on AI technologies, as well as potential future directions.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligenceclinical trialsdrug designdrug discoverydrug screening

Autor:innen und Institutionen

  • School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of…
  • Department of Respiratory Medicine of Affiliated Hospital, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.

Zitieren

APA

Wu, Y., Ma, L., Li, X., Yang, J., Rao, X., Hu, Y., Xi, J., Tao, L., Wang, J., Du, L., Chen, G., & Liu, S. (2024). The role of artificial intelligence in drug screening, drug design, and clinical trials. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1459954

Vancouver

Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y, et al. The role of artificial intelligence in drug screening, drug design, and clinical trials. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1459954

BibTeX
@article{Wu2024,
  author = {Wu, Yuyuan and Ma, Lijing and Li, Xinyi and Yang, Jingpeng and Rao, Xinyu and Hu, Yiru and Xi, Jingyi and Tao, Lin and Wang, Jianjun and Du, Lailing and Chen, Gongxing and Liu, Shuiping},
  title = {The role of artificial intelligence in drug screening, drug design, and clinical trials},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1459954}
}
Kostenlos starten →